dostarlimab
Selected indexed studies
- Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. (N Engl J Med, 2023) [PMID:36972026]
- Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial. (Ann Oncol, 2024) [PMID:38866180]
- Dostarlimab. (, 2012) [PMID:35849660]
_Worker-drafted node — pending editorial review._
Connections
dostarlimab is a side effect of
Sources
- Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. (2023) pubmed
- Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial. (2024) pubmed
- Dostarlimab. (2012) pubmed
- Dostarlimab. (2006) pubmed
- Dostarlimab: A Review. (2022) pubmed
- Dostarlimab: First Approval. (2021) pubmed
- Dostarlimab: A promising new PD-1 inhibitor for cancer immunotherapy. (2024) pubmed
- Dostarlimab: Review on success story and clinical trials. (2024) pubmed
- Dostarlimab in the treatment of mismatch repair deficient recurrent or advanced endometrial cancer. (2024) pubmed
- Dostarlimab and niraparib in primary advanced ovarian cancer. (2025) pubmed